Middle East and Africa Clinical Trial Imaging Market – Industry Trends and Forecast to 2029

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Middle East and Africa Clinical Trial Imaging Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Published Report
  • Sep 2022
  • MEA
  • 350 Pages
  • No of Tables: 77
  • No of Figures: 44

Middle East and Africa Clinical Trial Imaging Market, By Product and Services (Services and Software), Modality (Computed Tomography, Magnetic Resonance Imaging, Echocardiography, Nuclear Medicine, Positron Emission Tomography, X-ray, Ultrasound, Optical Coherence Tomography and Others), Application (Oncology, Neurology, Endocrinology, Cardiology, Dermatology, Hematology and Others), End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Medical Device Manufacturers, Academic and Government Research Institutes and Others), Distributor (Direct Sales and Tender Sales) - Industry Trends and Forecast to 2029.

Clinical Trial Imaging Market

Middle East and Africa Clinical Trial Imaging Market Analysis and Insights

The increasing demand for imaging technology, followed by rise in the prevalence of chronic diseases due to rise in elderly population and strategic initiatives by market players such as product launch, advancement, acquisition and agreements are the factors that are expected to drive the market growth.

Clinical Trial Imaging Market

Clinical Trial Imaging Market

However, improper and unfavourable reimbursement scenarios for imaging devices and lack of well-defined standards in clinical trial imaging instruments are expected to restrain the market growth.

The rising technological progressions in clinical trial imaging for diagnosis and treatment of chronic diseases are expected to drive market growth. Data Bridge Market Research analyzes that the Middle East and Africa clinical trial imaging market will grow at a CAGR of 6.5% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customisable to 2019-2014)

Quantitative Units

Revenue in USD Million and Pricing in USD

Segments Covered

By Product and Services (Services and Software), Modality (Computed Tomography, Magnetic Resonance Imaging, Echocardiography, Nuclear Medicine, Positron Emission Tomography, X-ray, Ultrasound, Optical Coherence Tomography and Others), Application (Oncology, Neurology, Endocrinology, Cardiology, Dermatology, Hematology and Others), End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Medical Device Manufacturers, Academic and Government Research Institutes and Others), Distributor (Direct Sales and Tender Sales)

Countries Covered

South Africa, Saudi Arabia, rest of Middle East and Africa

Market Players Covered

Resonance Health Analytical Services, Paraxel International Corporation, and WIRB-Copernicus Group

Market Definition

Clinical trial is a process of developing new drugs. It is designed for potential treatment and its effects on humans. Before the commercialization of new drugs, extensive clinical testing is done to identify promising compounds, and safety tests are conducted to determine the possible risks.

In clinical trials, medical imaging plays a significant role in more accurate and effective results. Different imaging technologies may be used to elucidate and demonstrate the mechanistic actions of drugs. Clinical trial imaging is the process of clinical analysis and medical intervention by creating image representations of inner parts of the body. It has several different technologies which are used to view the human body to monitor, treat, and diagnose medical conditions.

In the coming future, important decisions related to clinical trial imaging on drug discovery will be made by individuals who not only understand the biopsy but can also use the clinical trial imaging tools and the knowledge they release to develop hypotheses and identify quality targets

Middle East and Africa Clinical Trial Imaging Market Dynamics

Drivers

  • Rising R&D Expenditure

Imaging and pharma companies are continuously investing in R&D to offer innovative services for clinical trial imaging to customers and enhance their market presence. Medical imaging plays a dynamic role in clinical development. While the medical imaging industry is in a constant state of fluctuation due to implementation of new technologies in the market, the pharmaceutical and imaging industries continue to increase. This is attributed to enhanced investment in medical imaging companies along with mergers and acquisitions as well as the adoption of innovation in imaging technologies to support clinical trials for medical devices. Increasing R&D expenditure in pharmaceutical and biotechnological companies is fuelling market growth.

This has encouraged the development of new products and high research-oriented programs organized in biopharmaceutical industries and a high preference for the studies of human genome. Rising expenditure on R&D activities also develops new drugs and therapies to treat chronic diseases that boost market growth. This helps the pharmaceutical and biotechnological companies in the development of new technologies in the category of imaging clinical trials therefore, rising R&D expenditure is expected to drive the market growth.

  • Increasing Number of Contract Research Organizations (CROs)

Contract Research Organization (CRO) is an organization that gives support for clinical trials and other research services to imaging and pharmaceutical industries in the form of outsourced pharmaceutical research services in terms of both drugs and medical devices. CRO helps imaging and pharmaceutical industries with the drug development process to reduce the cost and initiate the process of bringing clinical trials to develop the drug for a particular disease segment by using clinical trial imaging and other processes to overcome capacity gaps of the in-house research team for pharmaceutical and clinical research.

A huge number of CROs are engaged in monitoring the drug development process such as PAREXEL (U.S.), PRA Health Sciences (U.S.), Labcorp (U.S.), PPD (U.S.), Syneos Health (U.S.), ICON plc (Ireland), Envigo (U.K.), Charles River (U.S.) and SGS (Switzerland) among others. These are some CROs that are engaged to give support for clinical trials and other research services to the imaging and pharmaceutical industries. The increasing number of CROs is expected to drive market growth.

Opportunities

  • Rise in Healthcare Expenditure

Healthcare expenditure has increased across the world as people's disposable income in various countries is increasing. Moreover, to accomplish the population requirements, government bodies and healthcare organizations are taking the initiative by virtue of accelerating healthcare expenditure.

For instance,

  • National Health Expenditure Accounts (NHEA) published a report which stated that the U.S. healthcare expenditure grew by 4.6% in 2019. This estimates USD 3.80 trillion for the overall U.S. population reported by U.S. Centers for Medicare (CMS) and GDP health, spending in the U.S. is accounted to reach 17.7%.

Growing healthcare expenditure is also beneficial for further growth in the economic and healthcare sector and it is primarily fruitful as it significantly affects the development of better and advanced medical products in the market. Therefore, the surge in healthcare expenditure is expected to create a greater opportunity for the market.

  • Strategic Initiatives by Market Players

The demand for clinical trial imaging is increasing in the market owing to the increased levels of R&D along with the growth of clinical trial imaging market aided by the desire for innovative medications. Thus, the top market players have implemented a new strategy by developing new products and collaborating with other market players to improve business operations and profitability.

For instance,

  • In February 2020, ICON plc acquired MedPass International, a European medical devices CRO, reimbursement and regulatory consultancy. This acquisition has reportedly helped in the expansion of the medical device and diagnostic research services of ICON in Europe.

These strategic initiatives by the market players, including acquisition, conferences and focused segment product launches, are helping them grow and improve the company's product portfolio, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players may act as an opportunity for market growth.

Restraints/Challenges

  • High-Risk Radiation Causing Diseases

In clinical medical imaging, radiation is absorbed by the body which can harm molecular structures inside the patient’s body. High doses of radiation can affect human cells including loss of hair, skin burns and increased incidence of cancer. The estimated risk of developing fatal cancer is one in 2000 after going through a radiation dose of 10 mSv in a CT scan.

For instance,

  • According to Radiological Society of America (RSNA), 1% to 2% of all cancers in the U.S. are caused by CT scans and the American Cancer Society identified CT scans and X-rays as one of the reasons for breast cancer, brain cancer and other cancers
  • According to the Center for Disease Control and Prevention, exposure to high levels of radiation results in acute radiation syndrome. The amount of radiation that a person's body absorbs is called the radiation dose.

The high-risk radiation that occurs, would decrease the usage and sale of clinical trial imaging devices, thereby affecting the credibility of manufacturers involved in this market. Therefore, the high-risk radiation-causing diseases are expected to restrain the market growth.

  • Strict Regulatory Policies

The healthcare industry is regulated by a structure of laws, rules & regulations that are extensive and complex.

For instance,

  • In April 2018, the U.S. FDA released updated Guidance for Clinical Trial Imaging Endpoint Process Standards for the industry which includes the quality of imaging data obtained in clinical trials
  • Biotechnology and pharmaceutical industries need to take first approval from the FDA for the process of drug development. They have to submit an Investigational New Drug (IND) application to the FDA before beginning clinical research.

COVID-19 Impact on the Middle East and Africa Clinical Trial Imaging Market

Diagnostic imaging services have been time-consuming and complicated by the need for strict infection control and prevention practices developed to contain the risk of transmission and protect healthcare personnel. Hence, the decision to image suspected patients or COVID-19-positive patients is based on their impact on the improvement of patient status.

For instance,

  • Researchers from the University of California at Los Angeles (UCLA) and the University of Southern California (USC) are developing Magnetic Resonance Imaging (MRI) suits that can greatly reduce any transmission risks to radiologists, operators, and patients, according to a letter published in the Journal of the American College of Radiology. There was a perceived workload increase in general X-ray and Computed Tomography imaging procedures because they were the key modalities for the initial and follow-up investigations of COVID-19. However, there was adequate availability of PPE during the study period.  As a result, the limited availability of medical care for illnesses other than COVID-19 has had a negative influence on the number of medical imaging procedures performed globally.

Recent Developments

  • In January 2022, Clario partnered with XingImaging, a radiopharmaceutical production and Positron Emission Tomography (PET) acquisition company, to deliver PET imaging clinical trials for testing novel therapeutics in China. The partnership offers to share the joint resources and neuroscience experts of Clario and XingImaging to expedite the start-up of clinical trials and drug discovery in China.
  • In November 2021, Clario was formed. ERT and Bioclinica, merged to form Clario. The formation of the new company resulted in the distribution of clinical imaging software and services and rise in sales.

Middle East and Africa Clinical Trial Imaging Market Scope

Middle East and Africa clinical trial imaging market is segmented into five segments based on product and services, modality, application, end user, and distributor. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product and Services

  • Services
  • Software

Based on product and services, the market is segmented into services and software.

Modality

  • Computed Tomography
  • Magnetic Resonance Imaging
  • Echocardiography
  • Nuclear Medicine
  • Positron Emission Tomography
  • X-ray
  • Ultrasound
  • Optical Coherence Tomography
  • Others

Based on modality, the market is segmented into computed tomography, magnetic resonance imaging, echocardiography, nuclear medicine, positron emission tomography, X-ray, ultrasound, optical coherence tomography and others.

Application

  • Oncology
  •  Neurology
  •  Cardiology
  •  Endocrinology
  •  Dermatology
  •  Hematology
  •  Others

Based on application, the market is segmented into oncology, neurology, cardiology, endocrinology, dermatology, hematology and others.

End user

  • Contract Research Organizations
  • Pharmaceutical & Biotechnology Companies
  • Medical Device Manufacturers
  • Academic and Government Research Institutes
  • Others

Based on end user, the market is segmented into contract research organizations, pharmaceutical & biotechnology companies, medical device manufacturers, academic and government research institutes and others.

Distributor

  • Direct Sales
  •  Tender Sales

Clinical Trial Imaging Market

Based on distributor, the market is segmented into direct sales and tender sales.

Middle East and Africa Clinical Trial Imaging Market Regional Analysis/Insights

Middle East and Africa clinical trial imaging market is analyzed, and market size insights and trends are provided by regions, product and services, modality, application, end user, and distributor as referenced above.

The countries covered in this market report are South Africa, Saudi Arabia, rest of Middle East and Africa. Saudi Arabia is expected to dominate the market due to the role of Artificial Intelligence (AI) in medical imaging in Saudi Arabia. AI plays a vital role in radiology; it is important to ensure that radiologists and radiographers have at least a minimum understanding of the technology.

The country section of the report also provides individual market-impacting factors and changes in regulations in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and African brands and their challenges faced due to large or scarce competition from local and domestic brands impact on sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Middle East and Africa Clinical Trial Imaging Market Share Analysis

The Middle East and Africa clinical trial imaging market competitive landscape provides details on the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, the Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the Middle East and Africa clinical trial imaging market.

Some of the major players operating in the market are Navitas Life Sciences, Resonance Health Analytical Services, BioTelemetry, a Philips Company, IXICO plc, ICON plc, anagram 4 clinical trials, Quotient Sciences, WORLDCARE CLINICAL, Clario, Paraxel International Corporation, Median Technologies, Perspectum, Calyx, WIRB-Copernicus Group, and Invicro.LLC among others.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCTS AND SERVICES LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

5 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING R&D EXPENDITURE

6.1.2 INCREASING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS (CROS)

6.1.3 INCREASING INCIDENCE OF CHRONIC DISEASES

6.1.4 GROWTH IN THE PHARMACEUTICAL AND IMAGING INDUSTRIES

6.2 RESTRAINTS

6.2.1 HIGH-RISK RADIATION CAUSING DISEASES

6.2.2 HIGH IMPLEMENTATION COST OF IMAGING SYSTEMS

6.3 OPPORTUNITIES

6.3.1 RISE IN HEALTHCARE EXPENDITURE

6.3.2 STRATEGIC INITIATIVES BY KEY PLAYERS

6.3.3 DEVELOPMENT OF INNOVATIVE IMAGING MODALITIES AND CONTRAST AGENTS

6.4 CHALLENGES

6.4.1 STRICT REGULATORY POLICIES

6.4.2 COST OF CLINICAL TRIALS

7 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET, BY PRODUCTS & SERVICES

7.1 OVERVIEW

7.2 SERVICES

7.2.1 OPERATIONAL IMAGING SERVICES

7.2.2 READ ANALYSIS SERVICES

7.2.3 TRIAL DESIGN CONSULTING SERVICES

7.2.4 SYSTEM AND TECHNICAL SUPPORT SERVICES

7.3 SOFTWARE

8 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET, BY MODALITY

8.1 OVERVIEW

8.2 COMPUTED TOMOGRAPHY

8.3 MAGENTIC RESONANCE IMAGING

8.4 ECHOCARDIOGRAPHY

8.5 NUCLEAR MEDICINE

8.6 POSITRON EMISSION TOMOGRAPHY

8.7 X-RAY

8.8 ULTRASOUND

8.9 OPTICAL COHERENCE TOMOGRAPHY

8.1 OTHERS

9 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 ONCOLOGY

9.2.1 X-RAY

9.2.2 ULTRASOUND

9.2.3 COMPUTED TOMOGRAPHY

9.2.4 MAGNETIC RESONANCE IMAGING

9.2.5 NUCLEAR MEDICINE

9.2.6 POSITRON EMISSION TOMOGRAPHY

9.2.7 OPTICAL COHERENCE TOMOGRAPHY

9.2.8 ECHOCARDIOGRAPHY

9.2.9 OTHERS

9.3 NEUROLOGY

9.3.1 COMPUTED TOMOGRAPHY

9.3.2 MAGNETIC RESONANCE IMAGING

9.3.3 POSITRON EMISSION TOMOGRAPHY

9.3.4 NUCLEAR MEDICINE

9.3.5 X-RAY

9.3.6 ULTRASOUND

9.3.7 OPTICAL COHERENCE TOMOGRAPHY

9.3.8 ECHOCARDIOGRAPHY

9.3.9 OTHERS

9.4 CARDIOLOGY

9.4.1 ECHOCARDIOGRAPHY

9.4.2 MAGNETIC RESONANCE IMAGING

9.4.3 COMPUTED TOMOGRAPHY

9.4.4 POSITRON EMISSION TOMOGRAPHY

9.4.5 NUCLEAR MEDICINE

9.4.6 X-RAY

9.4.7 ULTRASOUND

9.4.8 OPTICAL COHERENCE TOMOGRAPHY

9.4.9 OTHERS

9.5 ENDOCRINOLOGY

9.5.1 COMPUTED TOMOGRAPHY

9.5.2 MAGNETIC RESONANCE IMAGING

9.5.3 ECHOCARDIOGRAPHY

9.5.4 POSITRON EMISSION TOMOGRAPHY

9.5.5 NUCLEAR MEDICINE

9.5.6 X-RAY

9.5.7 ULTRASOUND

9.5.8 OPTICAL COHERENCE TOMOGRAPHY

9.5.9 OTHERS

9.6 DERMATOLOGY

9.6.1 ULTRASOUND

9.6.2 X-RAY

9.6.3 MAGNETIC RESONANCE IMAGING

9.6.4 COMPUTED TOMOGRAPHY

9.6.5 OPTICAL COHERENCE TOMOGRAPHY

9.6.6 POSITRON EMISSION TOMOGRAPHY

9.6.7 NUCLEAR MEDICINE

9.6.8 ECHOCARDIOGRAPHY

9.6.9 OTHERS

9.7 HEMATOLOGY

9.7.1 ULTRASOUND

9.7.2 COMPUTED TOMOGRAPHY

9.7.3 MAGNETIC RESONANCE IMAGING

9.7.4 X-RAY

9.7.5 POSITRON EMISSION TOMOGRAPHY

9.7.6 NUCLEAR MEDICINE

9.7.7 OPTICAL COHERENCE TOMOGRAPHY

9.7.8 ECHOCARDIOGRAPHY

9.7.9 OTHERS

9.8 OTHERS

10 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET, BY END USER

10.1 OVERVIEW

10.2 CONTRACT RESEARCH ORGANIZATION

10.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES

10.4 MEDICAL DEVICE MANUFACTURERS

10.5 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES

10.6 OTHERS

11 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR

11.1 OVERVIEW

11.2 DIRECT SALES

11.3 TENDER SALES

12 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET, BY REGION

12.1 MIDDLE EAST AND AFRICA

12.1.1 SAUDI ARABIA

12.1.2 SOUTH AFRICA

12.1.3 REST OF MIDDLE EAST AND AFRICA

13 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

14 SWOT ANALYSIS

15 COMPANY PROFILE

15.1 NAVITAS LIFE SCIENCES

15.1.1 COMPANY SNAPSHOT

15.1.2 COMPANY SHARE ANALYSIS

15.1.3 PRODUCT PORTFOLIO

15.1.4 RECENT DEVELOPMENTS

15.2 RESONANCE HEALTH ANALYTICAL SERVICES

15.2.1 COMPANY SNAPSHOT

15.2.2 REVENUE ANALYSIS

15.2.3 COMPANY SHARE ANALYSIS

15.2.4 PRODUCT PORTFOLIO

15.2.5 RECENT DEVELOPMENT

15.3 CLARIO

15.3.1 COMPANY SNAPSHOT

15.3.2 COMPANY SHARE ANALYSIS

15.3.3 PRODUCT PORTFOLIO

15.3.4 RECENT DEVELOPMENTS

15.4 PARAXEL

15.4.1 COMPANY SNAPSHOT

15.4.2 COMPANY SHARE ANALYSIS

15.4.3 PRODUCT PORTFOLIO

15.4.4 RECENT DEVELOPMENT

15.5 BIOTELEMETRY, A PHILIPS COMPANY

15.5.1 COMPANY SNAPSHOT

15.5.2 COMPANY SHARE ANALYSIS

15.5.3 PRODUCT PORTFOLIO

15.5.4 RECENT DEVELOPMENT

15.6 ICON PLC

15.6.1 COMPANY SNAPSHOT

15.6.2 REVENUE ANALYSIS

15.6.3 PRODUCT PORTFOLIO

15.6.4 RECENT DEVELOPMENTS

15.7 MEDIAN TECHNOLOGIES

15.7.1 COMPANY SNAPSHOT

15.7.2 REVENUE ANALYSIS

15.7.3 PRODUCT PORTFOLIO

15.7.4 RECENT DEVELOPMENT

15.8 PERSPECTUM

15.8.1 COMPANY SNAPSHOT

15.8.2 PRODUCT PORTFOLIO

15.8.3 RECENT DEVELOPMENTS

15.9 ANAGRAM 4 CLINICAL TRIALS

15.9.1 COMPANY SNAPSHOT

15.9.2 PRODUCT PORTFOLIO

15.9.3 RECENT DEVELOPMENT

15.1 CALYX

15.10.1 COMPANY SNAPSHOT

15.10.2 PRODUCT PORTFOLIO

15.10.3 RECENT DEVELOPMENT

15.11 IMAGE CORE LAB

15.11.1 COMPANY SNAPSHOT

15.11.2 PRODUCT PORTFOLIO

15.11.3 RECENT DEVELOPMENT

15.12 INVICRO. LLC. (A SUBSIDIARY OF KONICA MINOLTA)

15.12.1 COMPANY SNAPSHOT

15.12.2 REVENUE ANALYSIS

15.12.3 PRODUCT PORTFOLIO

15.12.4 RECENT DEVELOPMENTS

15.13 IXICO PLC

15.13.1 COMPANY SNAPSHOT

15.13.2 REVENUE ANALYSIS

15.13.3 PRODUCT PORTFOLIO

15.13.4 RECENT DEVELOPMENTS

15.14 QUOTIENT SCIENCES

15.14.1 COMPANY SNAPSHOT

15.14.2 PRODUCT PORTFOLIO

15.14.3 RECENT DEVELOPMENT

15.15 RADIANT SAGE LLC

15.15.1 COMPANY SNAPSHOT

15.15.2 PRODUCT PORTFOLIO

15.15.3 RECENT DEVELOPMENT

15.16 WIRB-COPERNICUS GROUP

15.16.1 COMPANY SNAPSHOT

15.16.2 PRODUCT PORTFOLIO

15.16.3 RECENT DEVELOPMENT

15.17 WORLDCARE CLINICAL

15.17.1 COMPANY SNAPSHOT

15.17.2 PRODUCT PORTFOLIO

15.17.3 RECENT DEVELOPMENT

16 QUESTIONNAIRE

17 RELATED REPORTS

List of Table

TABLE 1 COST OF CLINICAL TRIAL PHASE 2 AND PHASE 3

TABLE 2 HUGE R&D COST IN THE U.S. FOR DIFFERENT PHASES

TABLE 3 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET, BY PRODUCTS & SERVICES, 2020-2029 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCTS & SERVICES, 2020-2029 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA SOFTWARE IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA COMPUTED TOMOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA MAGNETIC RESONANCE IMAGING IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA ECHOCARDIOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA NUCLEAR MEDICINE IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA POSITRON EMISSION TOMOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA X-RAY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA ULTRASOUND IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA OPTICAL COHERENCE TOMOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA OTHERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA OTHERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA CONTRACT RESEARCH ORGANIZATION IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 MIDDLE EAST & AFRICA MEDICAL DEVICE MANUFACTURERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 MIDDLE EAST & AFRICA OTHERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 37 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA DIRECT SALES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA TENDER SALES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 42 MIDDLE EAST AND AFRICA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 43 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 44 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 45 MIDDLE EAST AND AFRICA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 46 MIDDLE EAST AND AFRICA NEUROLOGY CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 47 MIDDLE EAST AND AFRICA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION,2020-2029 (USD MILLION)

TABLE 48 MIDDLE EAST AND AFRICA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 49 MIDDLE EAST AND AFRICA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 50 MIDDLE EAST AND AFRICA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 51 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 52 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 53 SAUDI ARABIA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 54 SAUDI ARABIA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 55 SAUDI ARABIA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 56 SAUDI ARABIA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 57 SAUDI ARABIA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 58 SAUDI ARABIA NEUROLOGY CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 59 SAUDI ARABIA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 60 SAUDI ARABIA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 61 SAUDI ARABIA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 62 SAUDI ARABIA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 63 SAUDI ARABIA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 64 SAUDI ARABIA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 65 SOUTH AFRICA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 66 SOUTH AFRICA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 67 SOUTH AFRICA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 68 SOUTH AFRICA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 69 SOUTH AFRICA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 70 SOUTH AFRICA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 71 SOUTH AFRICA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 72 SOUTH AFRICA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 73 SOUTH AFRICA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 74 SOUTH AFRICA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 75 SOUTH AFRICA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 76 SOUTH AFRICA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 77 REST OF MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

List of Figure

FIGURE 1 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: SEGMENTATION

FIGURE 11 THE INCREASING NUMBER OF CONTRACT RESEARCH ORGANIZATION AND RISING R&D EXPENDITURE ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 SERVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET

FIGURE 14 WORLDWIDE BIOPHARMA COMPANIES R&D EXPENDITURE (IN USD MILLION)

FIGURE 15 THE MARKET GROWTH IN CLINICAL CRO (IN USD MILLIONS)

FIGURE 16 THE FUNCTION OF CRO

FIGURE 17 ESTIMATED NEW CANCER CASES, 2022

FIGURE 18 VALUE OF THE PHARMACEUTICAL SECTOR, WORLDWIDE, 2021 BY COUNTRY (IN MILLION U.S. DOLLARS)

FIGURE 19 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY PRODUCTS & SERVICES, 2021

FIGURE 20 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY PRODUCTS & SERVICES, 2022-2029 (USD MILLION)

FIGURE 21 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY PRODUCTS & SERVICES, CAGR (2022-2029)

FIGURE 22 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY PRODUCTS & SERVICES, LIFELINE CURVE

FIGURE 23 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY MODALITY, 2021

FIGURE 24 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY MODALITY, 2022-2029 (USD MILLION)

FIGURE 25 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY MODALITY, CAGR (2022-2029)

FIGURE 26 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY MODALITY, LIFELINE CURVE

FIGURE 27 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY APPLICATION, 2021

FIGURE 28 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY APPLICATION, 2022-2029 (USD MILLION)

FIGURE 29 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 30 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 31 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY END USER, 2021

FIGURE 32 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 33 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY END USER, CAGR (2022-2029)

FIGURE 34 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY END USER, LIFELINE CURVE

FIGURE 35 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY DISTRIBUTOR, 2021

FIGURE 36 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY DISTRIBUTOR, 2022-2029 (USD MILLION)

FIGURE 37 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY DISTRIBUTOR, CAGR (2022-2029)

FIGURE 38 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: BY DISTRIBUTOR, LIFELINE CURVE

FIGURE 39 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET: SNAPSHOT (2021)

FIGURE 40 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2021)

FIGURE 41 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2022 & 2029)

FIGURE 42 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2021 & 2029)

FIGURE 43 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET: BY PRODUCT & SERVICES (2022-2029)

FIGURE 44 MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET: COMPANY SHARE 2021 (%)]

View Detailed Information Right Arrow

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Middle East and Africa Clinical Trial Imaging Market are anticipated to soar at a CAGR of 6.5% outlook by 2029.
Its segmented Product and Services, Modality, Application, End User & Distributor
The countries covered in this market report are South Africa, Saudi Arabia, rest of Middle East and Africa. Saudi Arabia is expected to dominate the market due to the role of Artificial Intelligence (AI) in medical imaging in Saudi Arabia.